Articles for author: Ron Finklestien

January 5, 2024

Ron Finklestien

AAR Corp. Enters Into Multi-Year Distribution Deal With Ontic AAR Corp. Enters Into Multi-Year Distribution Deal With Ontic

AAR Corp. AIR entered into a multi-year agreement with Ontic. Viewed as a significant step forward, the agreement grants AAR the rights to provide a strategic selection of military products to the U.S. government, with exclusivity on specific parts. Simultaneously, Ontic, a reputed supplier of parts and services to the aircraft aftermarket, is poised to enhance its offerings to better assist American warfighters. AAR eagerly anticipates incorporating the Chatsworth, CA facility into its Ontic alliance, a move that is set to bolster its strategic military portfolio. Presently, AAR supports commercial distribution for Ontic’s Creedmoor, NC, plant, as well as military

January 5, 2024

Ron Finklestien

Medical Properties Trust Facing Unpaid Rent Drama Unpaid Rent Drama: Medical Properties Trust’s Stock Nosedives As Tenant Steward Struggles, Prompting New Loan

Stock Plunge Amid Tenant Woes Medical Properties Trust Inc MPW shares are plummeting, down around 15% following its disclosure to minimize exposure to tenant Steward Health Care System. As per the company’s third quarter 2023 Form 10-Q filing, Steward has delayed a portion of its September and October rent payment to MPT. Tenant’s Liquidity Woes Steward has cited significant changes in vendor payment terms that have adversely affected its liquidity, despite seeking additional working capital financing and attempting to sell its non-core laboratory business in Q4 2023. Protective Measures and Loan Arrangement To safeguard its assets and hospital operations, MPW has

January 5, 2024

Ron Finklestien

Downgrading Charles Schwab Reconsidering Charles Schwab: Downgrade Amid a Mixed Picture

Every crisis harbors investment opportunities. When the banking crisis erupted last year, my attention was swiftly drawn to the financial sector. Amid this flurry, one company stood out – The Charles Schwab Corporation (NYSE:SCHW), a formidable banking and brokerage behemoth. Despite intermittent weakness, its signs of growth were hard to ignore. Since my bullish article in September 2023, its shares have catapulted 20%, trouncing the S&P 500’s meager 6.5% ascent. Now, as the dust settles, I sense that the low-hanging fruit has been plucked. The recent share surge and persistent financial pain nudge me to recommend exploring other opportunities. Granted,

January 5, 2024

Ron Finklestien

Is CACI International Set to Rally Around 21%? A Look at 10 Top Analyst Forecasts For Friday CACI International Set to Rally?

Top Wall Street analysts have adjusted their outlook on various top companies. For a comprehensive view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for Invitation Homes Inc. INVH from $35 to $38. Keybanc analyst Austin Wurschmidt maintained an Overweight rating. Invitation Homes shares fell 0.3% to close at $33.98 on Thursday. See how other analysts view this stock. Needham boosted the price target for The Simply Good Foods Company SMPL from $42 to $45. Needham analyst Matt McGinley maintained a Buy rating. Simply Good Foods shares gained

January 5, 2024

Ron Finklestien

OneSpan’s Leadership Shake-Up and Financial Projections Update OneSpan’s Leadership Shake-Up and Financial Projections Update

jittawit.21/iStock via Getty Images OneSpan (NASDAQ:OSPN) fell 2.80% Friday pre-market after the software company announced interim CEO appointment and updated guidance. Victor Limongelli has been appointed interim CEO, effective immediately. Limongelli, who replaces Matthew Moynahan, most recently served as CEO at the SaaS company BQE Software. Additionally, OneSpan said it now expects 2023 revenue to be at the high end of the previously disclosed range of $228M-$232M, vs. consensus of $229.83M. 2023 adjusted EBITDA is expected to come in at or exceed the high end of the previously disclosed range of $2M-$4M. Also, the company reiterated its 2023 ARR guidance

January 5, 2024

Ron Finklestien

Insightful Investments: Identifying Potential Stocks in Market Downturn Insightful Investments: Identifying Potential Stocks in Market Downturn

Today’s episode of Full Court Finance at Zacks dives into the much-needed market pullback to start 2024, and why investors might want to start taking advantage of the downturn. The episode then digs into two highly-ranked stocks—Encompass Health (EHC)and Shift4 Payments (FOUR)—with strong growth potential in key industries that investors might want to buy amid the early 2024 cooldown.   Market Rebound Amidst Pullback The Nasdaq posted its fifth-straight drop on Thursday, marking its longest losing streak since October 2022. That might scare off some investors, but it’s worth constantly remembering that stocks without fail pull back to key moving averages

January 5, 2024

Ron Finklestien

First Solar Strikes Long-Term PPA Deal With Cleantech Solar

First Solar, Inc. FSLR has successfully sealed a 15-year power purchase agreement (PPA) with Cleantech Solar, marking a significant milestone for the renewable energy industry. Under the terms of the agreement, Cleantech Solar will develop 150 megawatts (MW) of photovoltaic (PV) solar and 16.8 MW of wind capacity in India’s Tamil Nadu. The Agreement in Detail Upon full commissioning, expected by the third quarter of 2024, the solar and wind assets of Cleantech Solar are anticipated to supply about 7.3 gigawatt-hours (GWh) of power to First Solar’s cutting-edge 3.3 GW solar manufacturing plant also located in Tamil Nadu. This will

January 5, 2024

Ron Finklestien

Insider Trades: Retractable Technologies and 3 Other Stocks Under $3 Insider Trades: Retractable Technologies and 3 Other Stocks Under $3

The Dow Jones index closed higher by around 10 points on Thursday. Insiders purchasing or selling shares indicates their confidence or concern around the company’s prospects. For investors and traders interested in penny stocks, this factor could be crucial in their overall investment or trading decision making. Below is a look at a few recent notable insider transactions for penny stocks. Cadiz The Deal: Cadiz Inc. CDZI CEO Susan P Kennedy acquired a total of 6,762 shares at an average price of $2.81, amounting to approximately $18,999. What’s Happening: Cadiz recently signed an agreement with San Bernardino County and water

January 5, 2024

Ron Finklestien

ZIM Integrated Shipping: Seizing the Opportunities of Red Sea Disruptions ZIM Integrated Shipping: Seizing the Opportunities of Red Sea Disruptions

Note: My previous coverage of ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) sets the stage for this update on the company. In a twist of fate, Israel-based liner company ZIM Integrated Shipping Services Ltd. (“ZIM”) appears to stand as one of the greatest beneficiaries of the ongoing Houthi attacks on merchant vessels in the Red Sea. Consequently, I am upgrading the company’s shares from “Hold” to “Speculative Buy” even at the risk of being late to the party. Bottom Line In a surprise twist of fate, the Houthis appear to have addressed worldwide containership over-capacities single-handedly, with Israel-based liner company ZIM

January 5, 2024

Ron Finklestien

Theravance Biopharma Faces Setback with Yupelri Trial Results Theravance Biopharma Faces Setback with Yupelri Trial Results

Photo by mi-viri/iStock via Getty Images Theravance Biopharma (NASDAQ:TBPH) experienced a staggering ~16% decline in premarket trading on Friday following the disappointing revelation that Yupelri, its FDA-approved therapy for chronic obstructive pulmonary disease (COPD), fell short of meeting the primary endpoint in a critical Phase 4 trial. Despite this setback, the company reported that the once-daily inhalation solution displayed a safety and tolerability profile consistent with its performance in previous clinical trials. The PIFR-2 trial, which compared Yupelri against Spiriva (tiotropium) – an FDA-approved medication marketed by German drug maker Boehringer Ingelheim for COPD patients, failed to demonstrate a statistically